Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers

Overview

Journal J Bone Metab

Date 2019 Dec 14

PMID 31832393

Citations 2

Authors

Seong Hee Ahn

So Young Park

Jun-Il Yoo

Youn-Jee Chung

Yun Kyung Jeon

Byung-Ho Yoon

Ha Young Kim

Seung Hun Lee

JeHoon Lee

Seongbin Hong

Affiliations

Soon will be listed here.

Abstract

Background: There has been interest in the clinical potential of bone turnover markers (BTMs) as tools both for assessing fracture risk and for monitoring treatment. However, the practical use of BTMs has been limited by their biological variability and difficulties in the interpretation of results. We investigated the current situation of application of BTMs by clinicians in Korea for the management of osteoporosis through a survey asking the patterns of BTMs prescription in clinical practice.

Methods: The survey was conducted online using the "google survey" by the BTM committee authorized by the Korean Society for Bone and Mineral Research.

Results: Total 108 clinicians responded the survey. Most of the respondents prescribed BTMs (80.6%) when they prescribed anti-osteoporotic medications (AOMs). The most frequently prescribed bone resorption and formation markers were serum C-terminal telopeptide of type I collagen (90.7%) and osteocalcin (65.1%), respectively. BTMs were mostly prescribed before starting AOMs (90.8%) and used for the purpose of evaluating treatment response (74.4%). Treatment response and compliance to AOMs were evaluated according to the change of absolute value of BTMs (55.1%). The respondents complained difficulties in the interpretation of BTMs (33.3%), the choice of proper BTMs (17.2%), and the proper sample preparation and handling (13.8%).

Conclusions: In Korea, most of clinicians recognized the benefit of BTMs in the management of osteoporosis. However, there are limitations in the broad use of these markers in clinical practice. Therefore, a clear recommendation for BTM in Korea enhances their use in clinical practice.

Citing Articles

Intra-Individual Changes in Total Procollagen-Type 1 N-terminal Propeptide in a Korean Adult Population.

Choi R, Lee S, Lee E Diagnostics (Basel). 2022; 12(10).

PMID: 36292087 PMC: 9601271. DOI: 10.3390/diagnostics12102399.

A Review of the Potential Application of Osteocyte-Related Biomarkers, Fibroblast Growth Factor-23, Sclerostin, and Dickkopf-1 in Predicting Osteoporosis and Fractures.

Ramli F, Chin K Diagnostics (Basel). 2020; 10(3).

PMID: 32155909 PMC: 7151094. DOI: 10.3390/diagnostics10030145.

References

Szulc P, Delmas P . Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008; 19(12):1683-704. DOI: 10.1007/s00198-008-0660-9. View

Hannon R, Eastell R . Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int. 2001; 11 Suppl 6:S30-44. DOI: 10.1007/s001980070004. View

Seibel M, Lang M, Geilenkeuser W . Interlaboratory variation of biochemical markers of bone turnover. Clin Chem. 2001; 47(8):1443-50. View

Bhattoa H . Laboratory aspects and clinical utility of bone turnover markers. EJIFCC. 2018; 29(2):117-128. PMC: 6053812. View

Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View

Szulc P, Naylor K, Hoyle N, Eastell R, Leary E . Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017; 28(9):2541-2556. DOI: 10.1007/s00198-017-4082-4. View

Vasikaran S, Eastell R, Bruyere O, Foldes A, Garnero P, Griesmacher A . Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420. DOI: 10.1007/s00198-010-1501-1. View

Brown J, Albert C, Nassar B, Adachi J, Cole D, Davison K . Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem. 2009; 42(10-11):929-42. DOI: 10.1016/j.clinbiochem.2009.04.001. View

Christiansen C, Riis B, RODBRO P . Prediction of rapid bone loss in postmenopausal women. Lancet. 1987; 1(8542):1105-8. DOI: 10.1016/s0140-6736(87)91671-0. View

10.

Kanis J, McCloskey E, Johansson H, Oden A, Melton 3rd L, Khaltaev N . A reference standard for the description of osteoporosis. Bone. 2008; 42(3):467-75. DOI: 10.1016/j.bone.2007.11.001. View

11.

Vasikaran S . Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci. 2008; 45(2):221-58. DOI: 10.1080/10408360801949442. View

12.

Bauer D, Garnero P, Hochberg M, Santora A, Delmas P, Ewing S . Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006; 21(2):292-9. DOI: 10.1359/JBMR.051018. View

13.

Delmas P, Vrijens B, Eastell R, Roux C, Pols H, Ringe J . Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007; 92(4):1296-304. DOI: 10.1210/jc.2006-1526. View

14.

Hans D, Goertzen A, Krieg M, Leslie W . Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011; 26(11):2762-9. DOI: 10.1002/jbmr.499. View

15.

Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P . National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012; 23(10):2425-33. PMC: 4011662. DOI: 10.1007/s00198-012-2049-z. View

16.

Bergmann P, Body J, Boonen S, Boutsen Y, Devogelaer J, Goemaere S . Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009; 63(1):19-26. PMC: 2705815. DOI: 10.1111/j.1742-1241.2008.01911.x. View

17.

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

18.

Park S, Ahn S, Yoo J, Chung Y, Jeon Y, Yoon B . Clinical Application of Bone Turnover Markers in Osteoporosis in Korea. J Bone Metab. 2019; 26(1):19-24. PMC: 6416153. DOI: 10.11005/jbm.2019.26.1.19. View

19.

Kanis J, Melton 3rd L, Christiansen C, JOHNSTON C, Khaltaev N . The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9(8):1137-41. DOI: 10.1002/jbmr.5650090802. View

20.

Garnero P, HAUSHERR E, CHAPUY M, Marcelli C, Grandjean H, Muller C . Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996; 11(10):1531-8. DOI: 10.1002/jbmr.5650111021. View